What's new in stroke?

R. G. Hart, J. J. Rohack, D. H. Solomon, W. M. Feinberg

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

More than 30,000 strokes occur each year in Texas, even though most strokes can be prevented by currently available and well-tolerated therapies. Antiplatelet therapy with aspirin or ticlopidine reduces stroke by about 25% in many patients with transient ischemic attack or initial stroke. Warfarin should not be used routinely for primary cerebrovascular disease but is useful to prevent cardioembolic stroke. Carotid endarterectomy is highly beneficial for patients with symptomatic, high-grade carotid stenosis, but its value for lesser degrees of symptomatic carotid plaque and for asymptomatic stenosis is less clear. Patients with nonvalvular atrial fibrillation have a substantial risk for stroke; most should be treated with warfarin. Risk-factor management (eg, control of hypertension, cessation of smoking, and treatment of hyperlipidemia) is as important as antithrombotic or surgical therapies for most patients with threatened stroke. Treating isolated systolic hypertension in elderly patients reduces stroke risk. Determining the cause of threatened stroke strongly influences preventive management. The tools are at hand to prevent most strokes; the challenge remains to apply them optimally.

Original languageEnglish (US)
Pages (from-to)46-55
Number of pages10
JournalTexas medicine
Volume91
Issue number5
StatePublished - May 1995

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hart, R. G., Rohack, J. J., Solomon, D. H., & Feinberg, W. M. (1995). What's new in stroke? Texas medicine, 91(5), 46-55.